Are these 5 cheapest NZX healthcare stocks?

Highlights 

  • The NZ healthcare sector is home to some of the world-famous healthcare companies.
  • TruScreen Group recently held its Annual Shareholder’s Meeting.
  • Blis Technologies announced the issue of performance share rights to select senior team members.

New Zealand boasts a well-established healthcare sector with some of the globally acclaimed healthcare companies and world-class retirement villages. One sector which remained unaffected by the pandemic was the healthcare sector, which saw unprecedented growth during this period.

As per reports, the NZ health care and social assistance industry employs nearly 209,000 salary and wage earners.

Having said that, let us look at the five famous and some of the most affordable healthcare stocks on the NZX.

TruScreen Group Limited (NZX:TRU)

Manufacturer of cancer screening devices, TruScreen Group Limited, had recently organised an online Annual Shareholder’s Meeting. Many resolutions were passed, including the election and re-election of Directors of the Company, as well as fixing the remuneration of its auditors, i.e., RSM Hayes Audit Auckland.

On 15 September, at the market close, TruScreen Group fell by 1.61% at NZ$0.061.

Related Read: Look at these 5 cheap NZX stocks under 50 cents

Image description: NZX healthcare stock Rua CFO’s quote

Image source: © 2021 Kalkine Media New Zealand Ltd, data source- Rua’s website

Rua Bioscience Limited (NZX:RUA)

Rua Bioscience Limited is NZ’s pharmaceutical company, producing medical cannabis both for domestic and international consumption.

Recently, the Company had published its FY21 financial results, which reflects RUA’s solid foundations for growth.

Its total investment in research and development stood at NZ$1.90 million, while cash and investments were recorded at NZ$16.4 million towards the year end.

Further in June this year, it had collaborated with the University of Waikato for a hyperspectral imaging project, thereby focusing on entry to the global cannabis testing industry.

At the closing bell, Rua Bioscience declined by 1.22% at NZ$0.405 on 15 September.

Related Read: Will Rua Bioscience’s (NZX:RUA) growth strategies pay off well?

Promisia Healthcare Limited (NZX:PHL)

Provider of personalised aged care, Promisia Healthcare Limited, appointed a new CEO, Chris Brown, last month.

Brown, who has held numerous senior management roles in companies like Contact Energy, aims to bring a strong skill set to the Company as PHL moves to the next phase of growth.

At the closing bell, Promisia Healthcare traded flat at NZ$0.001, on 15 September.

Interesting Read: How to diversify portfolio with NZX small-cap stocks?

Blis Technologies Limited (NZX:BLT)

Functioning as a biotechnology company, Blis Technologies Limited revealed the issue of performance share rights Tuesday.

The said shares were issued for no consideration to certain members of the senior management and leadership teams.

It is noted that these performance share rights were approved on 10 September by the Company's directors and the vesting period for the same is three years from the date of the grant of these shares.

On 15 September, Blis Technologies gained by 1.49% at NZ$0.066, at the end of the trading session.

Related Read: Are these the 5 most active stocks on NZX?

Fisher & Paykel Healthcare Corporation Limited (NZX:FPH; ASX:FPH)

The world-famous designer, developer, and supplier of products related to respiratory care is Fisher & Paykel Healthcare Corporation Limited. The healthcare giant has recently witnessed the inclusion of a non-executive director, Dr Lisa McIntyre.

Dr McIntyre would take charge of her office from October onwards. Also, she would be a member of the Quality, Safety, and Regulatory Committee.

It is noted that she would replace Tony Carter who sought retirement from the Board last month.

On 15 September, Fisher & Paykel Healthcare Corporation dropped by 0.86% at NZ$31.280, at the market close.

Must Read: What is Fisher & Paykel’s (NZX:FPH) stance for the rest of FY22?

Bottom Line

Healthcare stocks continue to flourish even during the prevailing conditions of COVID-19, as they focus on serving their customers and patients and are sure to get better with time.

Comment


Disclaimer

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK